HubertJamesFordIIIMD

Pulmonology • Chapel Hill, NC

Critical Care Medicine, Pleural Disease, Pulmonary Vascular Medicine

Associate Professor of Medicine, Director Pulmonary Hypertension Program, University of North Carolina at Chapel Hill

Join to view full profile

Dr. Ford is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ford's full profile

Already have an account?

Office
130 Mason Farm Rd
Cb 7020
Chapel Hill, NC 27599
Phone+1 919-966-2531

Education & Training

University of North Carolina HospitalsFellowship, Pulmonary Disease and Critical Care Medicine, 2005 - 2008
University of Miami/Jackson Health SystemResidency, Internal Medicine, 2002 - 2005
University of Miami Leonard M. Miller School of MedicineClass of 2002

Certifications & Licensure

NC State Medical License 2004 - 2025
FL State Medical License 2004 - 2006
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease

Clinical Trials

Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) Start of enrollment: 2011 Jun 24
Completed
Phase 2
Tadalafil for Sarcoidosis Associated Pulmonary Hypertension Start of enrollment: 2011 Mar 01
Completed
Phase 2, Phase 3
Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument Start of enrollment: 2013 Apr 01
Completed
Phase 3
Pulmonary Hypertension Association Registry Start of enrollment: 2015 Oct 01
Recruiting
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1-2 trial.
Mark T Gladwin, Victor R Gordeuk, Payal C Desai, Caterina Minniti, Enrico M Novelli
The Lancet. Haematology. 2024-05-01
5 citations
Prediction of patient outcomes through social determinants of health: The Pulmonary Hypertension Association Registry (PHAR) evaluation.
Dan Grinnan, Le Kang, Christine DeWilde, David Badesch, Raymond Benza
Pulmonary Circulation. 2022-07-01
12 citations
Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension As...
Hilary M. DuBrock, Charles D. Burger, Sonja Bartolome, Jeremy Feldman, D. Dunbar Ivy
Pulmonary Circulation. 2021-06-06